Geovax Labs (GOVX) Monkeypox Craze Up ✅🚀📣
GeoVax Labs (NASDAQ:GOVX) stock has gone parabolic and it’s easy to see why.
As the extent of the 2022 monkeypox outbreak keeps getting worse, this virus continues to be at the top of the headlines. It’s also been driving headlines in the financial media.
Companies like GOVX that stand to benefit from a monkeypox vaccination wave have received increased attention lately.
GOVX GeoVax Labs $2.80
Shares in the biotech firm have jumped nearly 5x since late last month. Given that such epic price moves were common last year during the “meme stock phenomenon,” you may think this stock’s turbo-charged rally is merely the latest example of “meme stock mania.”
While caution is warranted, I wouldn’t quickly take a hard pass on it. Take a look at the details. There’s enough substance to go along with the hype. Let’s dive in and see why there may be more upside despite the big jump it’s already experienced.
GOVX Stock and Monkeypox
Long a rare disease with a limited geographic presence, monkeypox (a viral infection) has gone global since May. It’s important to note that the total cases at present are just at just above 25,000. Given the nature of its transmittal, it likely will not spread to the extent of viruses like Covid-19.
Still, the outbreak is a concern. The Biden Administration has declared it a public health emergency. There’s also growing talk of ramping up production/distribution of monkeypox vaccines. That’s where GOVX stock comes into the picture.
Declaring this outbreak a public health emergency increases the chance that the U.S. Federal Government will help speed up the rollout of vaccine candidates. As InvestorPlace’s Chris MacDonald discussed last month, among its portfolio of vaccines, GeoVax Labs has one that has proven its viability against this virus.
Hence, this stock’s extreme price move last month was justified. It wasn’t on zero news or an overreaction on the part of retail traders. Even as it’s up big over a short timeframe, there may still be ample upside potential. Assuming, of course, this outbreak continues, and the push for widely available vaccines keeps growing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
$GeoVax Labs Inc(GOVX)$
Based on 1 Wall Street analysts offering 12 month price targets for GeoVax Labs in the last 3 months. The average price target is $6.00 with a high forecast of $6.00 and a low forecast of $6.00. The average price target represents a 246.82% change from the last price of $1.73.